Navigation Links
Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
Date:11/11/2009

SEATTLE, Nov. 11 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the three and nine months ended September 30, 2009 and provided a product pipeline update. Management will hold a conference call today at 4:30 p.m. ET, 1:30 p.m. PT (see below for details).

Oncothyreon reported a loss from operations of $2.8 million for the three months ended September 30, 2009, compared with a loss from operations of $3.6 million for the comparable period in 2008. Oncothyreon also reported a loss from operations of $9.0 million for the nine months ended September 30, 2009, compared with a loss from operations of $13.7 million for the comparable period in 2008. For both the three-month and nine-month periods, the decrease in loss from operations was primarily the result of decreased research and development, manufacturing and general and administrative expenses, offset by a decrease in revenue.

Operating expenses for the three and nine months ended September 30, 2009 were $2.8 million and $9.1 million respectively, compared with $4.4 million and $17.7 million for the comparable periods in 2008. Combined research and development and manufacturing expenses decreased to $1.3 million for the three months ended September 30, 2009 from $2.1 million for the three months ended September 30, 2008, and to $4.0 million from $9.5 million for the nine month periods, primarily as a result of the cessation of manufacturing activities for Stimuvax and the transfer of our Edmonton, Alberta facility to Merck KGaA. General and administrative expenses decreased to $1.4 million in the three months ended September 30, 2009 from $2.1 million in the three months ended September 30, 2008. General and administrative expenses decreased to $4.9 million in the first nine months of 2009 from $7.8 million in the first nine months o
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Oncothyreon announces webcast of third quarter 2009 financial results conference call
2. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
3. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
4. Oncothyreon reports second quarter 2009 financial results
5. Oncothyreon announces closing of $15.0 million registered direct financing
6. Oncothyreon announces webcast of second quarter 2009 financial results conference call
7. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
8. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
9. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
10. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
11. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 2014 Deep ... is a professional and in-depth research report ... provides basic Seaweed Fertilizer information, including Seaweed ... structure as well as industry overview. This ... domestic market as well as global industry ...
(Date:8/21/2014)... 21, 2014  Decision Resources Group finds that ... and Mexico currently ... newly approved agents, the anticipated label extension of ... launch of emerging biologics will substantially increase the ... emerging IL-5 inhibitors will introduce a new dynamic to ...
(Date:8/21/2014)... NJ (PRWEB) August 21, 2014 ... personal selling optimization technology and services for Life ... of “Grading Pharma’s Use of New Commercial Sales ... Measurement & Analytics. , The article examines some ... yield that are being tested in the pharmaceutical ...
(Date:8/20/2014)... 2014 Clintrax Global, Inc., a worldwide ... Raleigh, NC , recently announced the ... President of Administration. As Vice ... processes, including their alignment with company objectives and ... as an HR executive, specializing in needs assessments, ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Clintrax Global, Inc. Announces Addition to Executive Team 2
... EMERYVILLE, Calif., Jan. 2 Onyx,Pharmaceuticals, Inc. (Nasdaq: ... present,at the JPMorgan Healthcare Conference on Monday, January ... access a live webcast of the,presentation at:, ... listeners log on 15 minutes early in order ...
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced ... has filed a protocol with the U.S. ... 1/2 clinical trial for patients with,metastatic ovarian, ... and intraperitoneal administration of REOLYSIN(R), Oncolytics,proprietary formulation ...
... LOS GATOS, Calif., Dec. 31 Three ... announced that it has received 510(k) clearance,from ... for its WorkstationOne(TM),Breast Imaging Workstation. WorkstationOne is ... mammography images, and was developed with,the goal ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R) 2
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... sunscreen and seawater signals a relaxing trip to the ... beach vacation comes with an environmental hitch. When certain ... they can become toxic to some of the ocean,s ... other marine animals. Their study appears in the ACS ... Tovar-Sanchez and David Snchez-Quiles point out that other than ...
(Date:8/20/2014)... Wu Feng has built upon a National Science Foundation ... Cloud" program, and synergistically complemented it with subsequent collaborative ... Force on "big computing" for mini-drones and a $1 ... Health on "big data" for the life sciences. , ... each grant, he was able to tell a much ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... are under attack. Since 2006, more than a million have ... there has not been enough evidence to implicate the suspectuntil ... Geomyces destructans is the causal agent of White-nose Syndrome (WNS), ... is coauthored by Justin Boyles, a post-doctoral research associate in ...
... Dalhousie University in Nova Scotia have identified a key ... growth if their findings are confirmed. In ... journal of the American Association for Cancer Research, lead ... Biochemistry and Molecular Biology and Pathology, and Canada Research ...
... alphabet expanded. Scientists discovered that an extra letter or ... cells and brain cells. Now, researchers at Emory ... by that letter in the brains of mice, observing ... during development and aging. Those patterns, stable or ...
Cached Biology News:UT scientist helps confirm link between fungus and bat epidemic 2Key driver of metastasis identified 2Patterns of new DNA letter in brain suggest distinct function 2
Recombinant Feline IFN-alpha...
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
... MaV203 Competent Yeast Cells are designed ... (Figure 1). S. cerevisiae strain MaV203 contains ... genes for use with GAL4-based two-hybrid systems. ... mutations for selection of ProQuest bait and ...
Biology Products: